Literature DB >> 27051609

The role of technical assistance in expanding access to Xpert(®) MTB/RIF: experience in sub-Saharan Africa.

A N Umubyeyi1, F Bonsu2, R Chimzizi3, S Jemal4, M Melese4, E Ruttoh5, C Mundy6.   

Abstract

To improve tuberculosis (TB) diagnosis, many national TB programmes have committed to deploying Xpert(®) MTB/RIF. Implementation of this relatively new technology has suffered from a lack of comprehensive technical assistance, however, including the formulation of policies and plans to address operational issues. While providing technical assistance, we observed numerous operational challenges in the implementation and scale-up of Xpert in five sub-Saharan African countries: low coverage, poor laboratory infrastructure, limited access, poor linkages to treatment, inadequate data on outcomes, problems with specimen transport, diagnostic algorithms that are not aligned with updated World Health Organization recommendations on target patient groups and financing challenges. We recommend better country preparedness and training, laboratory information and quality systems, supply management and referral mechanisms.

Entities:  

Keywords:  TB diagnostic technology; TB laboratory services; Xpert; implementation of innovations; technical assistance

Year:  2016        PMID: 27051609      PMCID: PMC4809726          DOI: 10.5588/pha.15.0069

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  6 in total

1.  Xpert MTB/RIF assay for diagnosis of pleural tuberculosis.

Authors:  Sven O Friedrich; Florian von Groote-Bidlingmaier; Andreas H Diacon
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

2.  High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay.

Authors:  Stephen D Lawn; Andrew D Kerkhoff; Monica Vogt; Robin Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

3.  The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay.

Authors:  M Barnard; N C Gey van Pittius; P D van Helden; M Bosman; G Coetzee; R M Warren
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

4.  Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens.

Authors:  Heather J Zar; Lesley Workman; Washiefa Isaacs; Jacinta Munro; Faye Black; Brian Eley; Veronica Allen; Catharina C Boehme; Widaad Zemanay; Mark P Nicol
Journal:  Clin Infect Dis       Date:  2012-07-02       Impact factor: 9.079

5.  WHO's new end TB strategy.

Authors:  Mukund Uplekar; Diana Weil; Knut Lonnroth; Ernesto Jaramillo; Christian Lienhardt; Hannah Monica Dias; Dennis Falzon; Katherine Floyd; Giuliano Gargioni; Haileyesus Getahun; Christopher Gilpin; Philippe Glaziou; Malgorzata Grzemska; Fuad Mirzayev; Hiroki Nakatani; Mario Raviglione
Journal:  Lancet       Date:  2015-03-24       Impact factor: 79.321

6.  Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

Authors:  Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu
Journal:  BMC Infect Dis       Date:  2014-01-02       Impact factor: 3.090

  6 in total
  3 in total

Review 1.  Tuberculosis: Is the landscape changing?

Authors:  Sutapa Khatua; Abby M Geltemeyer; Anand Gourishankar
Journal:  Pediatr Res       Date:  2016-10-10       Impact factor: 3.756

2.  Evaluation of the Antibody in Lymphocyte Supernatant Assay to Detect Active Tuberculosis.

Authors:  Margaretha Sariko; Caitlin Anderson; Buliga S Mujaga; Jean Gratz; Stellah G Mpagama; Scott Heysell; Gibson Kibiki; Blandina Mmbaga; Eric Houpt; Tania Thomas
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

3.  Tuberculosis disease and infection among household contacts of bacteriologically confirmed and non-confirmed tuberculosis patients.

Authors:  Ken Warria; Peter Nyamthimba; Alex Chweya; Janet Agaya; Millicent Achola; Mary Reichler; Jessica Cowden; Charles M Heilig; Martien W Borgdorff; Kevin P Cain; Courtney M Yuen
Journal:  Trop Med Int Health       Date:  2020-04-06       Impact factor: 3.918

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.